5-hydroxytryptamine receptor 2C · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-135-hydroxytryptamine receptor 2C shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 13 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P28335. Start with schizophrenia, then reuse UniProt P28335 as the stable protein anchor across project notes and exports.
Start with schizophrenia, then reuse UniProt P28335 as the stable protein anchor across project notes and exports.
5-hydroxytryptamine receptor 2C shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block. 13 linked drugs remain visible in the same block.
Start review with schizophrenia because it currently carries approved-linked support. Linked drugs include AGOMELATINE, CHLORPROTHIXENE, LOXAPINE, LOXAPINE SUCCINATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxy5-hydroxytryptamine receptor 2C
Review this target as 5-hydroxytryptamine receptor 2C, mapped to UniProt P28335. Sequence length is 458 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 5-hydroxytryptamine receptor 2C as ChEMBL target CHEMBL225, mapped to UniProt P28335. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether 5-hydroxytryptamine receptor 2C is the right protein anchor across sources, using UniProt P28335 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why schizophrenia is currently framed as approved-linked support. It currently carries 13 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | 5-hydroxytryptamine receptor 2C |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P28335 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | 5-hydroxytryptamine receptor 2C |
| UniProt Accession | P28335 |
| Component Type | Protein |
| Sequence Length | 458 aa |
5-hydroxytryptamine receptor 2C
Review this target as 5-hydroxytryptamine receptor 2C, mapped to UniProt P28335. Sequence length is 458 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
5-hydroxytryptamine receptor 2C shows approved-linked disease relevance led by schizophrenia. 5 more disease programs remain visible in the same review block.
Start review with schizophrenia because it currently carries approved-linked support. Linked drugs include AGOMELATINE, CHLORPROTHIXENE, LOXAPINE, LOXAPINE SUCCINATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL149024 | 10.7 | Ki | 0.02 | Preclinical |
| CHEMBL4765074 | 10.2 | EC50 | 0.0631 | Preclinical |
| CHEMBL39 | 10.05 | EC50 | 0.09 | Clinical |
| CHEMBL609306 | 10.0 | EC50 | 0.1 | Preclinical |
| CHEMBL595195 | 10.0 | EC50 | 0.1 | Preclinical |
| CHEMBL4213447 | 10.0 | EC50 | 0.1 | Preclinical |
| CHEMBL494947 | 9.96 | EC50 | 0.11 | Preclinical |
| CHEMBL4213379 | 9.94 | EC50 | 0.116 | Preclinical |
| CHEMBL5078731 | 9.92 | IC50 | 0.12 | Preclinical |
| CHEMBL4765074 | 9.8 | Ki | 0.1585 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 479 | 1,173 | 6.8 |
| cell-based format | 254 | 1,812 | 7.0 |
| assay format | 18 | 221 | 7.5 |
| cell membrane format | 15 | 152 | 6.8 |
| tissue-based format | 3 | 6 | 7.0 |
| organism-based format | 1 | 55 | 7.4 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 199 | 917 | 7.1 |
| assay format | 44 | 79 | 7.3 |
| single protein format | 5 | 4 | 8.2 |
| tissue-based format | 1 | 1 | 5.8 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 9 | 34 | 6.4 |
| cell-based format | 4 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 1 | 5.5 |